spm²-safety projects & more
spm²-safety projects & more is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
Sponsor HepaRegeniX GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
Sponsor Heidelberg Pharma AG
- Start (EU)
- Latest update
- Estimated end
A pilot study of the safety and tolerability of oral administration of PD L 506 and the subsequent diagnostic value of porphyrin concentration (coproporphyrin I / III, CP I / III) in urine in patients with the first occurrence of colorectal cancer and in healthy subjects.
Sponsor Photonamic GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
Local and systemic safety and tolerability of ascending doses of TOP-N53, a nitric oxide (NO)-releasing phosphodiesterase-5 (PDE5) inhibitor, administered topically, on wound in patients with digital ulcers (DU) in systemic sclerosis (SSc) in an open-label, vehicle-controlled, phase 2a, multi-center clinical trial
Sponsor Topadur Pharma Deutschland GmbH
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
Sponsor Immatics US Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
Sponsor Cellcentric Limited
- Start (EU)
- Latest update
- Estimated end
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, as Monotherapy or in Combination with a Checkpoint Inhibitor in Patients with Recurrent and/or Refractory Solid Tumors
Sponsor Immatics Biotechnologies GmbH
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome
Sponsor Calliditas Therapeutics Suisse S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Sponsor Affimed GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for spm²-safety projects & more?
The 2026-10-09 snapshot links spm²-safety projects & more to 14 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Medical expertise, SAE processing, Development Safety Update Reports (DSUR) writing and submission to authorities, Signal Management Quarterly reviews. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for spm²-safety projects & more?
The most frequently recorded therapeutic areas are Gastroenterology, Haematological Malignancies, Solid Tumor Oncology, Dermatology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to spm²-safety projects & more conducted?
The linked trials record locations in 17 countries, including Germany, Spain, France, Netherlands, Poland. These are trial locations, not confirmed office locations or countries where spm²-safety projects & more delivered services.
What can this page tell me about spm²-safety projects & more's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under spm²-safety projects & more. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- spm²-safety projects & more GmbH